Autopsy report · NCT04535102

POLA+BR for Relapsed or Refractory DLBCL

“Lack of sufficient patient population”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Colorado, Denver

Sponsor type

University, hospital or other

Conditions

Diffuse Large B Cell Lymphoma

Interventions

Polatuzumab Vedotin

Participants

0

Trials that died the same way

• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
  “Lack of patient population” (95% match in meaning)
• Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
  “Lack of patients” (84% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (82% match in meaning)
• Ridge Preservation Comparing Simultaneous vs. Delayed Grafting
  “Not enough patients available” (81% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.